Lazaroid U-83836E improves tolerance to hemorrhagic shock and limb ischemia and reperfusion in rats and increases cardiac heat shock protein 72.
OBJECTIVE
Aminosteroids of the lazaroid type protect organs from ischemia-reperfusion damage. The authors hypothesized that lazaroid U-83836E may be beneficial in a shock model with hemorrhage combined with limb ischemia. Furthermore, the authors hypothesized that lazaroids induce expression of heat shock proteins (HSPs) of the 72-kDa family.


METHODS
Rats were divided into two groups (lazaroid and control groups, n = 8 each) and pretreated with the lazaroid U-83836E (5 mg/kg) or with vehicle intraperitoneally at 12 and 24 hours before experiments. At the time of the experiment, rats were anesthetized, and the femoral artery of each rat was cannulated. After 20 minutes of stabilization, blood was shed from each rat to bring its mean arterial pressure to 24-28 mmHg for 2 hours. Bilateral tourniquets were tightened proximally on the rat thighs during those 2 hours and then released. Shed blood plus equal amounts of Ringer acetate then were infused to restore normal blood pressure, followed by a continuous infusion of Ringer acetate, the rate of which was regulated to maintain blood pressure, until 30 minutes after start of resuscitation. Fluid resuscitation was stopped, and rats were observed for another 3.5 hours. At the end of the observation period, the rats' hearts were collected for immunoblot analysis of HSP72. Additional hearts were collected from similarly pretreated rats not undergoing the episode of hemorrhagic shock and fluid resuscitation.


RESULTS
Pretreatment with U-83836E improved mean arterial blood pressure after hemorrhagic shock and fluid resuscitation (p = 0.02), combined with improvements in acid-base balance (improved base excess and standard bicarbonate; p = 0.02 and p = 0.01, respectively). Western blot of cardiac protein extracts demonstrated that lazaroid pretreatment increased expression of HSP72.


CONCLUSIONS
Pretreatment with the lazaroid U-83836E improved outcome markers in this hemorrhagic shock model. The observed protection may be caused by increased expression of HSP72.
Labruto
Fausto
F
Crafoord Laboratory for Experimental Surgery, Karolinska Institutet, Stockholm, Sweden. lampo18@yahoo.com
Song
Xiaoliang
X
Valen
Guro
G
Vaage
Jarle
J
D000136:Acid-Base Equilibrium / Q000187:drug effects; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002839:Chromans / Q000494:pharmacology*; D004195:Disease Models, Animal; D050884:HSP72 Heat-Shock Proteins / Q000378:metabolism*; D007511:Ischemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D015427:Reperfusion Injury / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D012771:Shock, Hemorrhagic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000975:Antioxidants; D015415:Biomarkers; D002839:Chromans; D050884:HSP72 Heat-Shock Proteins; D010879:Piperazines; C066382:U 78517F